Cargando…

Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer

BACKGROUND: Cytotoxic T-lymphocyte (CTL) infiltration into tumor is a positive prognostic factor in breast cancer. High tumor mutational burden (TMB) is also considered as a predictor of tumor immunogenicity and response to immunotherapy. However, it is unclear whether the infiltration of functional...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuta, Eriko, Yan, Li, Opyrchal, Mateusz, Kalinski, Pawel, Takabe, Kazuaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024454/
https://www.ncbi.nlm.nih.gov/pubmed/33868461
http://dx.doi.org/10.1177/17588359211006680
_version_ 1783675312135995392
author Katsuta, Eriko
Yan, Li
Opyrchal, Mateusz
Kalinski, Pawel
Takabe, Kazuaki
author_facet Katsuta, Eriko
Yan, Li
Opyrchal, Mateusz
Kalinski, Pawel
Takabe, Kazuaki
author_sort Katsuta, Eriko
collection PubMed
description BACKGROUND: Cytotoxic T-lymphocyte (CTL) infiltration into tumor is a positive prognostic factor in breast cancer. High tumor mutational burden (TMB) is also considered as a predictor of tumor immunogenicity and response to immunotherapy. However, it is unclear whether the infiltration of functional CTL simply reflects the TMB or represents an independent prognostic value. METHODS: Utilizing The Cancer Genome Atlas (TCGA) breast cancer cohort, we established the Functional Hotness Score (FHS). The associations of FHS and breast cancer patient prognosis as well as distinct immunity markers were analyzed in a total of 3011 breast cancer patients using TCGA, METABRIC and metastatic breast cancer (MBC) cohort GSE110590. RESULTS: We established FHS, based on CD8A, GZMB and CXCL10 gene expression levels of bulk tumors, which delivered the best prognostic value among some gene combinations. Breast cancer patients with the high-FHS tumors showed significantly better survival. FHS was lower in the MBCs. Triple-negative breast cancer (TNBC) showed the highest FHS among subtypes. FHS predicted patient survival in hormone receptor (HR)-negative, especially in TNBC, but not in HR-positive breast cancer. FHS predicted patient prognosis independently in TNBC. The high-FHS TNBCs showed not only higher CD8+ T cell infiltration, but also enhanced broader type-1 anti-cancer immunity. The patients with the high-FHS tumors showed better prognosis not only in high-TMB tumors but also in low-TMB TNBCs. The combination of high-TMB with high-FHS identified a unique subset of patients who do not recur over time in TNBC. CONCLUSION: TNBCs with high FHS based on the expression levels of CD8A, GZMB and CXCL10 showed improved prognosis with enhanced anti-cancer immunity regardless of TMB. FHS constitutes an independent prognostic marker of survival, particularly robustly when combined with TMB in TNBC.
format Online
Article
Text
id pubmed-8024454
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-80244542021-04-16 Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer Katsuta, Eriko Yan, Li Opyrchal, Mateusz Kalinski, Pawel Takabe, Kazuaki Ther Adv Med Oncol TNBC in 2019: Promising Signals for the Treatment of a Formidable Disease BACKGROUND: Cytotoxic T-lymphocyte (CTL) infiltration into tumor is a positive prognostic factor in breast cancer. High tumor mutational burden (TMB) is also considered as a predictor of tumor immunogenicity and response to immunotherapy. However, it is unclear whether the infiltration of functional CTL simply reflects the TMB or represents an independent prognostic value. METHODS: Utilizing The Cancer Genome Atlas (TCGA) breast cancer cohort, we established the Functional Hotness Score (FHS). The associations of FHS and breast cancer patient prognosis as well as distinct immunity markers were analyzed in a total of 3011 breast cancer patients using TCGA, METABRIC and metastatic breast cancer (MBC) cohort GSE110590. RESULTS: We established FHS, based on CD8A, GZMB and CXCL10 gene expression levels of bulk tumors, which delivered the best prognostic value among some gene combinations. Breast cancer patients with the high-FHS tumors showed significantly better survival. FHS was lower in the MBCs. Triple-negative breast cancer (TNBC) showed the highest FHS among subtypes. FHS predicted patient survival in hormone receptor (HR)-negative, especially in TNBC, but not in HR-positive breast cancer. FHS predicted patient prognosis independently in TNBC. The high-FHS TNBCs showed not only higher CD8+ T cell infiltration, but also enhanced broader type-1 anti-cancer immunity. The patients with the high-FHS tumors showed better prognosis not only in high-TMB tumors but also in low-TMB TNBCs. The combination of high-TMB with high-FHS identified a unique subset of patients who do not recur over time in TNBC. CONCLUSION: TNBCs with high FHS based on the expression levels of CD8A, GZMB and CXCL10 showed improved prognosis with enhanced anti-cancer immunity regardless of TMB. FHS constitutes an independent prognostic marker of survival, particularly robustly when combined with TMB in TNBC. SAGE Publications 2021-04-05 /pmc/articles/PMC8024454/ /pubmed/33868461 http://dx.doi.org/10.1177/17588359211006680 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle TNBC in 2019: Promising Signals for the Treatment of a Formidable Disease
Katsuta, Eriko
Yan, Li
Opyrchal, Mateusz
Kalinski, Pawel
Takabe, Kazuaki
Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
title Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
title_full Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
title_fullStr Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
title_full_unstemmed Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
title_short Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
title_sort cytotoxic t-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
topic TNBC in 2019: Promising Signals for the Treatment of a Formidable Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024454/
https://www.ncbi.nlm.nih.gov/pubmed/33868461
http://dx.doi.org/10.1177/17588359211006680
work_keys_str_mv AT katsutaeriko cytotoxictlymphocyteinfiltrationandchemokinepredictlongtermpatientsurvivalindependentlyoftumormutationalburdenintriplenegativebreastcancer
AT yanli cytotoxictlymphocyteinfiltrationandchemokinepredictlongtermpatientsurvivalindependentlyoftumormutationalburdenintriplenegativebreastcancer
AT opyrchalmateusz cytotoxictlymphocyteinfiltrationandchemokinepredictlongtermpatientsurvivalindependentlyoftumormutationalburdenintriplenegativebreastcancer
AT kalinskipawel cytotoxictlymphocyteinfiltrationandchemokinepredictlongtermpatientsurvivalindependentlyoftumormutationalburdenintriplenegativebreastcancer
AT takabekazuaki cytotoxictlymphocyteinfiltrationandchemokinepredictlongtermpatientsurvivalindependentlyoftumormutationalburdenintriplenegativebreastcancer